Fig. 1.

MI reverses the inhibitory effect of erastin on tumor growth. a Schematic presentation on the time-line of in vivo cell transplantation; b–d Representative images of echocardiographs and statistical data on ejection fraction (EF%), fractional shortening (FS%) (N = 6–7/group); e, f qRT-PCR analysis on the expression of ANP, BNP with heart tissues (N = 6/group); g–i Representative images of tumors with corresponding (g) tumor volumes and (i) tumor weights in sham or MI C57BL/6 mice bearing LLC cells with erastin treatment (N = 6–7/group); j Representative images of H&E and immunohistochemistry for 4-HNE staining and the higher magnifications of indicated area were shown at the top right corner. Quantification of 4-HNE intensity as % of total area (Bar: 20 μm) (N = 6/group); k The lipid formation was measured by MDA assay (N = 6/group); l, m qRT-PCR analysis on the expression of PTGS2 and GPX4 from subcutaneous xenograft tissues in LLC tumor-bearing model (N = 6/group). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001